BVXV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 Sep 2023 @ 15:59):

Stats
Today's Volume	22 668.00
Average Volume	38 939.00
Market Cap	4.97M
EPS	ILS0 ( 2023-11-29 )
Last Dividend	ILS0 ( N/A )
Next Dividend	ILS0 ( N/A )
P/E	-0.579
ATR14	ILS0.0550 (6.88%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-01	Margolin Yael	Sell	133 200	Restricted Share Units
2023-01-01	Margolin Yael	Sell	0	Ordinary Shares
2023-01-01	Laster Morris C	Sell	133 200	Restricted Share Units
2023-01-01	Laster Morris C	Sell	0	Ordinary Shares
2023-01-01	Lowell George	Sell	133 200	Restricted Share Units

INSIDER POWER
-100.00
Last 23 transactions
Buy: 0 \| Sell: 12 745 600

Volume Correlation

Long: 0.06 (neutral)

Short: -0.15 (neutral)

Signal:(16.452) Neutral

BiondVax Pharmaceuticals Correlation

10 Most Positive Correlations
ODT	0.975
OPTN	0.97
TCDA	0.969
TTCF	0.966
STSA	0.962
FNWD	0.951
SNCE	0.95
PLXP	0.943
HIBB	0.938
AGRI	0.936

10 Most Negative Correlations
BIOS	-0.955
CCRC	-0.955
SVFA	-0.95
OXUS	-0.943
SLAM	-0.942
SVFAU	-0.942
TZPSU	-0.941
ALPA	-0.94
COCO	-0.94
SCOB	-0.94

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BiondVax Pharmaceuticals Correlation - Currency/Commodity

-0.09
( neutral )

-0.29
( neutral )

0.00
( neutral )

0.74
( moderate )

-0.31
( neutral )

-0.02
( neutral )

BiondVax Pharmaceuticals Financials

Annual	2022
Revenue:	ILS0
Gross Profit:	ILS0 (0.00 %)
EPS:	ILS0

Q2	2023
Revenue:	ILS0
Gross Profit:	ILS0 (0.00 %)
EPS:	ILS-1.110

Q1	2023
Revenue:	ILS2.02M
Gross Profit:	ILS2.02M (100.00 %)
EPS:	ILS-1.190

Q4	2022
Revenue:	ILS0
Gross Profit:	ILS0 (0.00 %)
EPS:	ILS0

Financial Reports:

No articles found.

BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.